StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — Sandip Sabharwal

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

bySandip SabharwalHorizon: 1–3 months23 Sept 2026via ET Now (Live)

Entry₹1,851.3Inferred
Target₹1,920
Total upside +3.71% (call closed)
Stop loss₹1,825-1.42% risk
Exit₹1,82530 Sept 2026, 12:09 pm
Stop-loss hit-1.42%
Follow Sandip Sabharwal for new calls(25% target hit, 12 closed calls)Get alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 1 active Short-term call on SUNPHARMASee 84 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 30 Sept 2026
4 supporting1 neutral1 opposing
Supports the BUY call (4)

13 advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · adjacent horizon·29 Sept · yesterday

Sun Pharmaceutical has entered into a licensing agreement for lerodalcibep, a novel drug candidate, expanding its specialty portfolio.

BSE · Company Update·28 Sept · 2d ago

(opens in new tab)

Sun Pharma participated in a White House ceremony, announcing agreements with the U.S. government to prioritize access to affordable medicines. The company committed to Most Favored Nation (MFN) prici

BSE · Company Update·1 Sept · 4w ago

(opens in new tab)

4 other SEBI-registered advisors have active short-term BUY calls on this stock

Advisor consensus · same horizon·30 Jul · 2mo ago

Neutral / worth noting (1)

Sun Pharmaceutical Industries Ltd has been assigned international issuer credit ratings by Moody's Ratings (Baa1, Stable Outlook) and S&P Global Ratings (BBB+, Stable Outlook). These ratings are inves

BSE · Company Update·8 Sept · 3w ago

(opens in new tab)
Weighs against the BUY call (1)

Sun Pharma subsidiaries settle US generic drug pricing antitrust case for confidential amount

NewsCnbc-Tv18·11 Sept · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from Sandip Sabharwal

Every call and its outcome